Latest Ecs Botanics Holdings (Asx:Ecs) News

Page 1 of 1
ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.
Ada Torres
Ada Torres
16 Dec 2025
ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.
Ada Torres
Ada Torres
4 Dec 2025
ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.
Ada Torres
Ada Torres
21 Nov 2025
ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.
Ada Torres
Ada Torres
13 Nov 2025
ECS Botanics reports a positive cash flow milestone in Q1 FY26, driven by strong direct-to-consumer sales and operational efficiencies, while preparing for a European market debut.
Ada Torres
Ada Torres
7 Oct 2025
ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.
Ada Torres
Ada Torres
29 Aug 2025
ECS Botanics Holdings Ltd reported a $5.7 million net loss for FY2025 amid a strategic pivot from B2B to B2C sales and significant impairments. The company aims for a turnaround in FY2026 driven by new product launches and expanded production capacity.
Ada Torres
Ada Torres
29 Aug 2025
ECS Botanics reports a 20% quarterly surge in direct-to-consumer sales and a record medicinal cannabis harvest, supported by an expanded loan facility to fuel further growth.
Ada Torres
Ada Torres
28 July 2025
ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.
Ada Torres
Ada Torres
7 July 2025
ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.
Ada Torres
Ada Torres
30 June 2025
ECS Botanics is on track for a record-breaking FY25 harvest with a 50% production increase and new premium product launches, signaling strong growth and a positive cash flow outlook.
Ada Torres
Ada Torres
16 May 2025
ECS Botanics reports a striking 339% quarter-on-quarter growth in its B2C sales, offsetting a slight dip in total revenue as it pivots to a hybrid B2B and B2C business model. The company’s record harvest and new product launches position it for a promising turnaround.
Ada Torres
Ada Torres
28 Jan 2025